Baxter International (BAX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Proposal to amend the Certificate of Incorporation to reduce the minimum number of directors from nine to seven and eliminate the maximum number, with the exact number to be set by the Board.
Board adopted a Bylaws Amendment to fix Board size within a range of seven to twelve members, effective only if the Charter Amendment is approved.
Amendments aim to provide flexibility for Board size adjustments and support ongoing Board refreshment and succession planning.
Clear parameters for Board size changes are established, with future changes to be moved to the Charter upon next amendment approval.
Board recommends voting in favor of the Proposed Charter Amendment.
Board of directors and corporate governance
Framework preserves Board's ability to adjust its size as needed for effective decision making.
Intended to ensure an optimal mix of skills, perspectives, and experiences on the Board.
Bylaws Amendment maintains disciplined parameters for Board size, consistent with governance best practices.
Shareholder rights and capital structure
Stockholders retain assurance that Board size changes will occur within clearly defined and disciplined parameters.
Stockholders can change their vote if they have already voted against the Proposed Charter Amendment.
Latest events from Baxter International
- Q1 2026 sales up 3% reported, adjusted EPS down 35%, full-year outlook reiterated.BAX
Q1 202630 Apr 2026 - Q4 sales up 8% but adjusted EPS down 24%; 2026 outlook flat with margin recovery expected.BAX
Q4 202512 Apr 2026 - Shareholders will vote on key governance, compensation, and board structure changes, all recommended for approval.BAX
Proxy filing23 Mar 2026 - Shareholders to vote on director elections, executive pay, auditor, and board size changes.BAX
Proxy filing23 Mar 2026 - Proxy seeks approval for Board refreshment, pay practices, auditor, and sustainability focus.BAX
Proxy Filing13 Mar 2026 - Oil price exposure halved, new operating model boosts efficiency, and margin recovery expected.BAX
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Stable fundamentals, prudent 2026 outlook, and focus on innovation and deleveraging.BAX
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day26 Feb 2026 - Q2 sales and adjusted EPS beat guidance; net loss from goodwill impairment; guidance raised.BAX
Q2 20242 Feb 2026 - Separation of the kidney business and operational focus set the stage for growth and margin expansion.BAX
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026